Abnormal Interpretations by Indication for Examination for 401,548 Diagnostic Mammography Examinations from 2007 - 2013
Based on BCSC data through 2013
| Work-Up of Abnormal Screening Exams | Short-Interval Follow-Up | Evaluation of Breast Problem/ No Lump or Lump Unknown | Evaluation of Breast Problem/ Palpable Lump | All Diagnostic Exams | |
|---|---|---|---|---|---|
| Abnormal Interpretation Rate* | 17.00% | 5.20% | 9.30% | 18.70% | 12.60% |
| Abnormal final interpretations | 21,941 | 2,672 | 6,941 | 6,615 | 50,659 |
| All examinations | 128,976 | 51,440 | 74,426 | 35,308 | 401,548 |
| PPV2‡ | 26.90% | 19.60% | 26.70% | 34.50% | 27.50% |
| Cancers | 5,909 | 525 | 1,853 | 2,279 | 13,915 |
| Abnormal final interpretations | 21,941 | 2,672 | 6,941 | 6,615 | 50,659 |
| PPV3§ | 29.20% | 23.40% | 31.00% | 37.70% | 30.40% |
| Cancers | 5,726 | 505 | 1,760 | 2,143 | 10,725 |
| Abnormal final interpretations, with known biopsy | 19,621 | 2,158 | 5,681 | 5,687 | 35,275 |
Notes:
Numbers are frequencies unless otherwise indicated.
The first non-zero assessment within 90 days was used as the final assessment for analysis.
** Includes 94,228 exams from one registry for which sub-classification of diagnostic indication (e.g., additional evaluation, short interval follow-up, etc.) was not available.
* Abnormal interpretation rate = the percentage of examinations with an abnormal final interpretation
(BI-RADS category 4 or 5; Note: 0 or 3 with a recommendation for biopsy was recoded as 4).
‡ PPV2 = the percentage of examinations with an abnormal final interpretation
that result in a tissue diagnosis of cancer within 1 year.
§ PPV3 = the percentage of examinations with an abnormal final interpretation,
where it is known that a biopsy was performed as a result of the abnormal diagnostic examination,
that result in a tissue diagnosis of cancer within 1 year. (Excludes Chicago)
Table numbers last updated Mar 26, 2017.
Numbers are frequencies unless otherwise indicated.
The first non-zero assessment within 90 days was used as the final assessment for analysis.
** Includes 94,228 exams from one registry for which sub-classification of diagnostic indication (e.g., additional evaluation, short interval follow-up, etc.) was not available.
* Abnormal interpretation rate = the percentage of examinations with an abnormal final interpretation
(BI-RADS category 4 or 5; Note: 0 or 3 with a recommendation for biopsy was recoded as 4).
‡ PPV2 = the percentage of examinations with an abnormal final interpretation
that result in a tissue diagnosis of cancer within 1 year.
§ PPV3 = the percentage of examinations with an abnormal final interpretation,
where it is known that a biopsy was performed as a result of the abnormal diagnostic examination,
that result in a tissue diagnosis of cancer within 1 year. (Excludes Chicago)
Table numbers last updated Mar 26, 2017.
The following must be cited when reproducing this data:
"The Breast Cancer Surveillance Consortium and its data collection and sharing activities are funded by the National Cancer Institute (P01CA154292). Downloaded xx/xx/xxxx from the Breast Cancer Surveillance Consortium Web site - http://www.bcsc-research.org/."